---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078102"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:52:22.382684+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cellectar to pursue accelerated NDA for iopofosine I 131 in WM; Q2 net loss $5.4M

## Summary
- Plans NDA submission for accelerated approval of iopofosine I 131 in WM, subject to sufficient funding and confirmatory trial initiation.
- FDA granted Breakthrough Therapy Designation for iopofosine I 131; EMA decision on conditional approval expected late Q3/early Q4 2025.
- Raised ~$9.5M in June/July financings; cash $11.0M at June 30, 2025, plus July net proceeds funds operations into Q2 2026.
- CLR 125 Phase 1 TNBC trial protocol submitted to FDA; plan to advance into clinic 4Q 2025/early 2026.
- Q2 2025 net loss $5.4M ($3.39 per share); R&D $2.4M, G&A $3.6M; both down YoY.

## SEC filing metadata
- accession: 0001104659-25-078102
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465925078102/0001104659-25-078102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465925078102/tm2523504d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078102
- JSON: https://secwatch.observer/filing/0001104659-25-078102.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.